Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Active not recruiting 6Completed 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 1

Interventions

Rituximab 30Cyclophosphamide 25Filgrastim 19Methotrexate 15fludarabine phosphate 13Etoposide 13Cytarabine 13Peripheral Blood Stem Cell Transplantation 12Cyclosporine 11Vincristine 10Mycophenolic Acid 10Whole-Body Irradiation 9Antilymphocyte Serum 9Radiotherapy 8Granulocyte Colony-Stimulating Factor 8CT-P10 8fludarabine 7Prednisone 7Doxorubicin 7Dexamethasone 7merphos 6Tacrolimus 6Melphalan 6Calcium Dobesilate 6dexamethasone acetate 5dexamethasone 21-phosphate 5deltacortene 5auricularum 5Methylprednisolone 5Leucovorin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Burkitt Lymphoma × N,N-dicyclohexyl-isoborneol-10-sulfonamide × Clear all
NCT03518112 2022-11-04

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 10 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡